FWFang Wang

Fang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fang Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Yuyu Niu

    State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China

    3 shared publications
  • Weizhi Ji

    State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China

    2 shared publications
  • Yu Kang

    State Key Laboratory of Primate Biomedical Research; Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China

    2 shared publications
  • Baohong Tian

    State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, China

    1 shared publication
  • Chengting Zhang

    State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China

    1 shared publication
  • Chu Chu

    State Key Laboratory of Primate Biomedical Research and Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, China

    1 shared publication

Latest Publications

  • Open Access

    β-catenin loss drives nuclear lamina aging through enhancer dysfunction and β-TrCP-mediated proteostasis

    by Jiao Yang, Fang Wang, Longmei Gong, Fan Li, Xuebin Qi, Weizhi Ji, Chengting Zhang, Lin Liu, Yuyu Niu

  • Open Access

    Cloning and base editing of GFP transgenic rhesus monkey and off-target analysis

    by Yu Kang, Shaoxing Dai, Yuqiang Zeng, Fang Wang, Pengpeng Yang, Zhaohui Yang, Youwei Pu, Zifan Li, Xinglong Chen, Baohong Tian, et al.

    We report the cloning of a 12-year-old transgenic green fluorescent protein (GFP) monkey by somatic cell nuclear transfer (SCNT) and base editing of the embryos, accompanied with safety evaluation of adenine base editors (ABEs). We first show the ability of ABEmax to silence GFP through A-to-G editing of the GFP sequence in 293T cells. Subsequently, using donor cells from a monkey expressing GFP, we have successfully generated 207 ABEmax-edited (SCNT-ABE) and 87 wild-type (SCNT) embryos for embryo transfer, genotyping, and genome and transcriptome analysis. SCNT-ABE and SCNT embryos are compared for off-target analysis without the interference of genetic variants using a new method named as OA-SCNT. ABEmax does not induce obvious off-target DNA mutations but induces widespread off-target RNA mutations, 35% of which are exonic, in edited monkey embryos. These results provide important references for clinical application of ABE.


  • Open Access

    CRISPR/Cas9-mediated genome editing in nonhuman primates

    by Yu Kang, Chu Chu, Fang Wang, Yuyu Niu

    Owing to their high similarity to humans, non-human primates (NHPs) provide an exceedingly suitable model for the study of human disease. In this Review, we summarize the history of transgenic NHP models and the progress of CRISPR/Cas9-mediated genome editing in NHPs, from the first proof-of-principle green fluorescent protein-expressing monkeys to sophisticated NHP models of human neurodegenerative disease that accurately phenocopy several complex disease features. We discuss not only the breakthroughs and advantages, but also the potential shortcomings of the application of the CRISPR/Cas9 system to NHPs that have emerged from the expanded understanding of this technology in recent years. Although off-target and mosaic mutations are the main concerns in CRISPR/Cas9-mediated NHP modeling, recent progress in genome editing techniques make it likely that these technical limitations will be overcome soon, bringing excellent prospects to human disease studies.